[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-363314-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-363314-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","spliceosomal-component-snrpe-drives-cell-proliferation-by-regulating-ctp-synthase-1-mrna-splicing-in-ovarian-cancer","Spliceosomal component SNRPE drives cell proliferation by regulating CTP synthase 1 mRNA splicing in ovarian cancer","","The study investigates how alternative splicing contributes to sustained proliferation in ovarian cancer. SNRPE is found overexpressed in ovarian cancer, especially the proliferative subtype, correlating with worse clinical outcomes. SNRPE knockdown slows proliferation by inducing G1 arrest and apoptosis. RNA-seq identifies CTPS1 as a key downstream effector, with SNRPE loss causing intron 15 retention, NMD-mediated degradation of unspliced CTPS1 transcripts, and reduced functional CTPS1 levels, thereby suppressing tumor progression.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/spliceosomal-component-snrpe-drives-cell-proliferation-by-regulating-ctp-synthase-1-mrna-splicing-in-ovarian-cancer/363314/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/spliceosomal-component-snrpe-drives-cell-proliferation-by-regulating-ctp-synthase-1-mrna-splicing-in-ovarian-cancer/363314.png","ImageObject",300,407,{"name":42,"@type":43},"Stanford","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-01","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What role does SNRPE play in ovarian cancer proliferation?","Question",{"text":63,"@type":64},"SNRPE is overexpressed in ovarian cancer, particularly in the proliferative subtype, and its knockdown significantly slows tumor cell proliferation by causing G1 phase arrest and apoptosis.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does SNRPE affect CTPS1 mRNA processing?",{"text":68,"@type":64},"SNRPE deficiency leads to retention of intron 15 in CTPS1 mRNA, which triggers nonsense-mediated mRNA decay (NMD) of unspliced transcripts and reduces the level of functional CTPS1.",{"name":70,"@type":61,"acceptedAnswer":71},"Why does CTPS1 suppression matter for tumor progression in this model?",{"text":72,"@type":64},"CTPS1 knockdown significantly suppresses tumor progression driven by SNRPE overexpression, supporting CTPS1 as a critical downstream effector of the SNRPE pathway.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},363314,1790194691,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},2336477552062,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Oncogene [www.nature.com/onc](www.nature.com/onc)  \nARTICLE OPEN   \nSpliceosomal component SNRPE drives cell proliferation by regulating CTP synthase 1 mRNA splicing in ovarian cancer  \nYingying Pu1,2,3, Zhongshao Chen1,2, Qianqian Gao1,2, Yanling Liu1,2,4, Ning Yang 1,2, Yingwei Li 1,2,5 ✉ and Beihua Kong 1,2 ✉  \n© The Author(s) 2026  \n|  |  |  |\n| --- | --- | --- |\n|  | Sustained proliferation is a hallmark of tumor cells. Cancer-associated alternative splicing (AS) events can provide proliferative advantages in tumors, suggesting that identifying aberrant RNA splicing events linked to proliferation in ovarian cancer (OC) may reveal novel therapeutic targets. In this study, we found that small nuclear ribonucleoprotein polypeptide E (SNRPE) was overexpressed in OC, particularly in the proliferative subtype, and indicated worse clinical prognosis. SNRPE knockdown signiﬁcantly slowed tumor cell proliferation, inducing G1 phase cell cycle arrest and apoptosis. RNA sequencing analysis identiﬁed CTP synthase 1(CTPS1), the rate-limiting factor in the conversion of UTP to CTP, as a critical downstream effector of SNRPE. Mechanistically, SNRPE deﬁciency led to the retention of intron 15 in CTPS1 mRNA, triggering the degradation of unspliced transcripts through the nonsense-mediated mRNA decay (NMD) pathway and reducing the level of functional CTPS1 . Notably, CTPS1 knockdown signiﬁcantly suppressed the tumor progression driven by SNRPE overexpression. Given that the loss of CTPS2 was prevalent in OC, OC cell proliferation could be more effectively controlled by the suppression of CTPS1 . We propose a strategy to regulate CTPS1 expression by modulating its efﬁcient splicing through SNRPE. Consequently, the SNRPE-CTPS1 axis may represent a potential |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| therapeutic target for OC patients. |  |  |\n|  | Oncogene (2026) 45:1645–1659; [https://doi.org/10.1038/s41388-026-03764-2](https://doi.org/10.1038/s41388-026-03764-2) |  |\n|  |  |  |\n\nINTRODUCTION  \nOvarian cancer (OC) ranks ﬁrst in terms of mortality rate among gynecological malignancies, with approximately 324,398 new cases and 206,839 deaths reported globally in 2022 [1] . More than 70% of OC patients present with advanced-stage disease at diagnosis because of obscure symptoms at onset, rapid progression, and the absence of reliable early detection methods. Despite the development of targeted therapies, primarily antiangiogenic agents and PARP inhibitors, improvements in the prognosis of OC are limited because of its propensity for extensive abdominal metastasis, tumor recurrence, and drug resistance. The overall 5-year survival rate of patients with OC is only 30–50%[2] .  \nSustained proliferation is a hallmark of tumor cells and represents a pivotal process in the development and progression of cancer [3] . Targeting mechanisms involved in uncontrolled cancer cell proliferation represents an efﬁcient therapeutic strategy [4] . Several targeted compounds against tumor cell proliferation have been developed in recent years [5] . Notably, recent studies have revealed that OC patients with a proliferative subtype have shorter survival but may derive relatively greater therapeutic beneﬁts from anti-angiogenic treatments [6, 7] . Consequently, identifying key molecular drivers underlying OC pathogenesis and progression, particularly those associated with proliferation, elucidating their mechanistic roles, and exploring  \nnovel targeted therapeutic strategies are of paramount importance for improving clinical outcomes in OC patients.  \nAlternative splicing (AS) is a key posttranscriptional regulatory mechanism through which eukaryotic cells increase their transcriptomic and proteomic diversity [8] . Aberrant splicing events are common in cancer and are associated with mutations or altered expression of components related to the splicing machinery [9] . Advances in ","cbCaitxnPLsgSKkj","https://ap.wps.com/l/cbCaitxnPLsgSKkj","pdf",5769068,15,"English","# Introduction\n## Ovarian cancer burden and prognosis\n## Proliferation as a tumor hallmark\n## Alternative splicing and therapeutic targeting\n## Spliceosome components in ovarian cancer","[{\"question\":\"What role does SNRPE play in ovarian cancer proliferation?\",\"answer\":\"SNRPE is overexpressed in ovarian cancer, particularly in the proliferative subtype, and its knockdown significantly slows tumor cell proliferation by causing G1 phase arrest and apoptosis.\"},{\"question\":\"How does SNRPE affect CTPS1 mRNA processing?\",\"answer\":\"SNRPE deficiency leads to retention of intron 15 in CTPS1 mRNA, which triggers nonsense-mediated mRNA decay (NMD) of unspliced transcripts and reduces the level of functional CTPS1.\"},{\"question\":\"Why does CTPS1 suppression matter for tumor progression in this model?\",\"answer\":\"CTPS1 knockdown significantly suppresses tumor progression driven by SNRPE overexpression, supporting CTPS1 as a critical downstream effector of the SNRPE pathway.\"}]","Spliceosomal component SNRPE drives cell proliferation by regulating CTP synthase 1 mRNA splicing in ovarian cancer | PDF",1790150786,38,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/235ec9a65fdcc6ed4f2f41b7913b4f05.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bfc7ed455cd5cc43f2caae56540c8ebb.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/75c286a4645cb8142f27ec1732f882c0.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1ef338e673127c37789928b178ee4a0e.webp",980,1301]